Target family: Coronavirus (CoV) proteins (type: other_protein)
Target: CoV Papain-like protease

Ligand: XR8-24 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.409999847412109 pIC50
Reference (Journal): Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.
Published in: J Med Chem

Ligand: XR8-24 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 6.429999828338623 pKd
Reference (Journal): Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.
Published in: J Med Chem

Ligand: XR8-23 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.409999847412109 pIC50
Reference (Journal): Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.
Published in: J Med Chem

Ligand: XR8-23 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 6.630000114440918 pKd
Reference (Journal): Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.
Published in: J Med Chem

Ligand: PLpro inhibitor 7 [PMID: 36977673] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.03000020980835 pIC50
Reference (Journal): Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2.
Published in: Nat Commun

Ligand: PF-07957472 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pKi
Reference (Journal): Discovery of SARS-CoV-2 papain-like protease (PLpro) inhibitors with efficacy in a murine infection model
Published in: bioRxiv

Ligand: ML364 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): USP2 inhibition prevents infection with ACE2-dependent coronaviruses in vitro and is protective against SARS-CoV-2 in mice.
Published in: Sci Transl Med

Ligand: GRL-0617 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.21999979019165 pIC50
Reference (Journal): A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication.
Published in: Proc Natl Acad Sci USA

Ligand: GRL-0617 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors.
Published in: Nat Commun

Ligand: GRL-0617 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease.
Published in: ACS Infect Dis

Ligand: GRL-0617 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 4.96999979019165 pKd
Reference (Journal): Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2.
Published in: Cell Chem Biol

Ligand: ebselen (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.699999809265137 pIC50
Reference (Journal): Ebselen as a highly active inhibitor of PLProCoV2
Published in: bioRxiv

Ligand: compound 4 [PMID: 33531496] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.360000133514404 pIC50
Reference (Journal): Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors.
Published in: Nat Commun

Ligand: compound 19 [PMID: 33979649] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.360000133514404 pIC50
Reference (Journal): Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2.
Published in: Cell Chem Biol

Ligand: compound 19 [PMID: 33979649] (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 5.590000152587891 pKd
Reference (Journal): Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2.
Published in: Cell Chem Biol

Ligand: compound 12 [PMID: 38150587] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.230000019073486 pIC50
Reference (Journal): Allosteric Inhibitors of the SARS-COV-2 Papain-like Protease Domain Induce Proteasomal Degradation of Its Parent Protein NSP3.
Published in: ACS Chem Biol